Genocea Biosciences (NASDAQ:GNCAQ – Get Rating) is one of 277 publicly-traded companies in the "Biological products, except diagnostic" industry, but how does it contrast to its competitors? We will compare Genocea Biosciences to related companies based on the strength of its dividends, analyst recommendations, valuation, risk, profitability, earnings and institutional ownership.

Volatility & Risk

Genocea Biosciences has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500. Comparatively, Genocea Biosciences' competitors have a beta of 0.97, meaning that their average share price is 3% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Genocea Biosciences and its competitors, as provided by MarketBeat.

Earnings and Valuation

This table compares Genocea Biosciences and its competitors top-line revenue, earnings per share and valuation.

Genocea Biosciences' competitors have higher revenue and earnings than Genocea Biosciences. Genocea Biosciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 46.3% of shares of all "Biological products, except diagnostic" companies are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 16.3% of shares of all "Biological products, except diagnostic" companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Genocea Biosciences and its competitors' net margins, return on equity and return on assets.

Genocea Biosciences Company Profile

(Get Rating)

Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The firm uses its proprietary technology platform, ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-011, an investigational adoptive T cell therapy and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.